Performance of the EQ-5D-5L Plus Respiratory Bolt-On in the Birmingham Chronic Obstructive Pulmonary Disease Cohort Study.


Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
11 2021
Historique:
received: 15 10 2020
revised: 30 04 2021
accepted: 10 05 2021
entrez: 29 10 2021
pubmed: 30 10 2021
medline: 29 12 2021
Statut: ppublish

Résumé

A respiratory bolt-on dimension for the EQ-5D-5L has recently been developed and valued by the general public. This study aimed to validate the EQ-5D-5L plus respiratory dimension (EQ-5D-5L+R) in a large group of patients with chronic obstructive pulmonary disease (COPD). Validation was undertaken with data from the Birmingham COPD Cohort Study, a longitudinal UK study of COPD primary care patients. Data on the EQ-5D-5L+R were collected from 1008 responding participants during a follow-up questionnaire in 2017 and combined with (previously collected) data on patient and disease characteristics. Descriptive and correlation analyses were performed on the EQ-5D-5L+R dimensions and utilities, in relation to COPD characteristics and compared with the EQ-5D-5L without respiratory dimension. Multivariate regression models were estimated to test whether regression coefficients of clinical characteristics differed between the EQ-5D-5L+R utility and the EQ-5D-5L utility. Correlation coefficients for the EQ-5D-5L+R utility with COPD parameters were slightly higher than the EQ-5D-5L utility. Both instruments displayed discriminant validity but analyses in clinical subgroups of patients showed larger absolute differences in utilities for the EQ-5D-5L+R. In the multivariate analyses, only the coefficient for the COPD Assessment Test score was higher for the model using the EQ-5D-5L+R utility as outcome. This study showed that the addition of a respiratory domain to the EQ-5D-5L led to small improvements in the instrument's performance. Comparability of the EQ-5D across diseases, currently considered one of its strengths, would have to be traded off against a modest improvement in utility difference when adding the respiratory dimension.

Identifiants

pubmed: 34711368
pii: S1098-3015(21)01580-1
doi: 10.1016/j.jval.2021.05.006
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1667-1675

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2021 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Martine Hoogendoorn (M)

Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: hoogendoorn@imta.eur.nl.

Susan Jowett (S)

Health Economics Unit, University of Birmingham, Birmingham, England, UK.

Andrew P Dickens (AP)

Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK.

Rachel Jordan (R)

Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK.

Alexandra Enocson (A)

Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK.

Peymane Adab (P)

Institute of Applied Health Research, University of Birmingham, Birmingham, England, UK.

Matthijs Versteegh (M)

Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands.

Maureen Rutten-van Mölken (MR)

Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH